Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the Hyperlipidemia market grown in recent years?

In recent times, the hyperlipidemia market has seen consistent growth. The projection is that it’ll increase from a size of $20.24 billion in 2024 to $21.03 billion in 2025, with a compound annual growth rate (CAGR) of 3.9%. The historic period’s growth can be credited to factors like the increased demand for effective remedies, expansion into new regions, heightened public knowledge of hyperlipidemia, and the consumption of tobacco.

How is the hyperlipidemia market size expected to evolve during the forecast period?

It is anticipated that the market size of hyperlipidemia will experience consistent expansion in the upcoming years. The market is projected to reach $24.3 billion by 2029, with a compound annual growth rate (CAGR) of 3.7%. The surge in this duration can be credited to the escalating requirement for hyperlipidemia medicines, worldwide health campaigns, an increasing elderly population, preventive healthcare, and early intervention strategies. Significant trends expected during this forecast period are new treatment methods, the application of digital health technologies for managing hyperlipidemia, usage of biomarkers in hyperlipidemia detection and therapy, along with the research and development endeavors of pharmaceutical treatment options.

Get your hyperlipidemia market report here!

https://www.thebusinessresearchcompany.com/report/hyperlipidemia-global-market-report

Which key drivers are propelling the hyperlipidemia market’s growth?

The rise in chronic illnesses like heart disease is anticipated to stimulate the expansion of the hyperlipidemia market. Heart diseases impact the heart and its functionality. Those suffering from heart ailments can benefit from hyperlipidemia treatment as it lessens the chances of heart attacks, prevents strokes, enhances endothelial function, and reduces invasive intervention requirements. For instance, data released by the British Heart Foundation, a UK-based cardiovascular research charity, revealed that heart and circulatory diseases impact nearly 7.6 million people in the UK in September 2024, of which around 4 million are men and 3.6 million are women. These illnesses account for roughly 27% of all UK deaths, leading to over 170,000 deaths per annum or approximately 480 deaths daily, meaning one death occurs every three minutes. Therefore, the hyperlipidemia market grows with the increased occurrence of chronic heart conditions. Furthermore, the rising rate of tobacco use, associated with health risks commonly linked to hyperlipidemia such as obesity and insulin resistance, is anticipated to drive the growth of the hyperlipidemia market. Smoking, which entails the combustion of tobacco and inhalation of the smoke for taste, allows for the absorption of components into the blood. Over time, these factors can trigger dyslipidemia, an abnormal lipid level condition that may cause hyperlipidemia. Useful evidence of this trend can be seen in July 2022 data from Statistics Canada, a government agency, which reported a 5.8% increase in cigarette production compared to June 2021, with total cigarette sales peaking at 1.4 billion in June 2022. Hence, the proliferation of smoking is a significant driver of the hyperlipidemia market.

What are the market segments in the hyperlipidemia industry?

The hyperlipidemia market covered in this report is segmented –

1) By Type: Familial, Acquired

2) By Treatment: Statins, PCSK9 Inhibitors, Bile Acid Sequestrants, Cholesterol Absorption Inhibitors, Fibric Acid Derivatives, Combination, Other Treatment

3) By Route of Administration: Oral, Parenteral

4) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End Users

Subsegments:

1) By Familial Hyperlipidemia: Familial Hypercholesterolemia (FH), Familial Combined Hyperlipidemia, Familial Dysbetalipoproteinemia

2) By Acquired Hyperlipidemia: Diet-Related Hyperlipidemia, Secondary Hyperlipidemia, Drug-Induced Hyperlipidemia

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12873&type=smp

Which leading companies are shaping the growth of the hyperlipidemia market?

Major companies operating in the hyperlipidemia market are Pfizer Inc., Johnson and Johnson Limited, Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC., Bristol-Myers Squibb Company, GlaxoSmithKline plc., Eli Lilly and Co Ltd., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Otsuka Pharmaceutical Co. Ltd., Menarini Group, Ipsen S.A., Dr. Reddy’s Laboratories Ltd., Apotex Inc., Hikma Pharmaceuticals PLC, Cipla Inc., Endo International PLC, Aspen Pharmacare Holdings Limited, Zydus Lifesciences Ltd., LEO Pharma A/S.

What key trends are currently impacting the hyperlipidemia market’s development?

Predominant businesses in the hyperlipidemia market are investing in the creation of novel products including groundbreaking therapies to lower LDL cholesterol, with the aim of maintaining their market presence. For instance, in March 2024, Regeneron Pharmaceuticals, Inc., a biotech firm based in the U.S., revealed the approval of their product, Praluent (alirocumab) Injection, by the U.S. Food & Drug Administration (FDA). This is a significant progression in treating patients, especially children aged 8 and above, with heterozygous familial hypercholesterolemia (HeFH) by targeting perilously high LDL cholesterol (LDL-C) levels. The recent FDA approval indicates the successful results of the Phase 3 trials which resulted in reducing LDL-C levels by 31% during regular dosage. Given its proven safety track record consistent with adults and being the pioneering therapy to target the genetically-validated PCSK9 protein, Praluent sets a landmark in treating heart disease. Taken together, these characteristics underline Praluent as a valuable alternative for managing elevated cholesterol in HeFH children.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12873

Which geographic areas are influencing the growth of the hyperlipidemia market?

North America was the largest region in the hyperlipidemia market in 2024. The regions covered in hyperlipidemia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Browse Through More Similar Reports By The Business Research Company:

Fatty Amines Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/fatty-amines-global-market-report

Specialty Fats And Oils Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/specialty-fats-and-oils-global-market-report

Fats And Oils Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/fats-and-oils-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: